BAIRD MEDICAL INVESTMENT HOL (BDMD) Fundamental Analysis & Valuation
NASDAQ:BDMD • KYG0705H1039
Current stock price
2.02 USD
-0.01 (-0.49%)
At close:
2 USD
-0.02 (-0.99%)
After Hours:
This BDMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BDMD Profitability Analysis
1.1 Basic Checks
- BDMD had positive earnings in the past year.
- BDMD had a negative operating cash flow in the past year.
- In multiple years BDMD reported negative net income over the last 5 years.
- BDMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- BDMD has a better Return On Assets (16.24%) than 95.77% of its industry peers.
- The Return On Equity of BDMD (35.14%) is better than 98.41% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 24.25%, BDMD belongs to the top of the industry, outperforming 98.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.24% | ||
| ROE | 35.14% | ||
| ROIC | 24.25% |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BDMD has a better Profit Margin (33.76%) than 99.47% of its industry peers.
- The Operating Margin of BDMD (41.35%) is better than 100.00% of its industry peers.
- Looking at the Gross Margin, with a value of 88.17%, BDMD belongs to the top of the industry, outperforming 97.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. BDMD Health Analysis
2.1 Basic Checks
- BDMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- Compared to 1 year ago, BDMD has less shares outstanding
- Compared to 1 year ago, BDMD has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.97 indicates that BDMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.97, BDMD is doing good in the industry, outperforming 69.31% of the companies in the same industry.
- A Debt/Equity ratio of 0.56 indicates that BDMD is somewhat dependend on debt financing.
- BDMD has a Debt to Equity ratio (0.56) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.97 |
ROIC/WACC2.69
WACC9.01%
2.3 Liquidity
- BDMD has a Current Ratio of 1.71. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.71, BDMD is doing worse than 68.25% of the companies in the same industry.
- BDMD has a Quick Ratio of 1.67. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.67, BDMD perfoms like the industry average, outperforming 44.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.67 |
3. BDMD Growth Analysis
3.1 Past
- BDMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.58%, which is quite good.
- Looking at the last year, BDMD shows a quite strong growth in Revenue. The Revenue has grown by 17.74% in the last year.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BDMD Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 4.21, which indicates a rather cheap valuation of BDMD.
- Based on the Price/Earnings ratio, BDMD is valued cheaper than 97.88% of the companies in the same industry.
- When comparing the Price/Earnings ratio of BDMD to the average of the S&P500 Index (24.88), we can say BDMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.21 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 98.94% of the companies in the same industry are more expensive than BDMD, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 4.89 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BDMD Dividend Analysis
5.1 Amount
- BDMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BDMD Fundamentals: All Metrics, Ratios and Statistics
2.02
-0.01 (-0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-15 2025-05-15
Earnings (Next)N/A N/A
Inst Owners1.44%
Inst Owner ChangeN/A
Ins Owners49.82%
Ins Owner ChangeN/A
Market Cap74.19M
Revenue(TTM)37.04M
Net Income(TTM)12.50M
AnalystsN/A
Price TargetN/A
Short Float %7.7%
Short Ratio0.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.21 | ||
| Fwd PE | N/A | ||
| P/S | 2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.08 | ||
| P/tB | 2.09 | ||
| EV/EBITDA | 4.89 |
EPS(TTM)0.48
EY23.76%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.01
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.24% | ||
| ROE | 35.14% | ||
| ROCE | 36.88% | ||
| ROIC | 24.25% | ||
| ROICexc | 25.24% | ||
| ROICexgc | 25.27% | ||
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% | ||
| FCFM | N/A |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 210.97% | ||
| Cap/Sales | 6.52% | ||
| Interest Coverage | 24.84 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 2.97 |
F-Score2
WACC9.01%
ROIC/WACC2.69
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-249.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.28%
OCF growth 3YN/A
OCF growth 5YN/A
BAIRD MEDICAL INVESTMENT HOL / BDMD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BDMD.
What is the valuation status of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
ChartMill assigns a valuation rating of 3 / 10 to BAIRD MEDICAL INVESTMENT HOL (BDMD). This can be considered as Overvalued.
How profitable is BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
BAIRD MEDICAL INVESTMENT HOL (BDMD) has a profitability rating of 5 / 10.
What is the valuation of BAIRD MEDICAL INVESTMENT HOL based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BAIRD MEDICAL INVESTMENT HOL (BDMD) is 4.21 and the Price/Book (PB) ratio is 2.08.